[Form 4] SOPHiA GENETICS SA Insider Trading Activity

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,403 ordinary shares of SOPH on April 8, 2026. The shares were sold in open-market transactions at a weighted average price of about $4.85 per share to cover tax withholding from recently vested restricted stock units.

According to the disclosure, these sales were made under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After these transactions, Cardoza directly holds 291,458 ordinary shares, indicating the sale represents a small portion of his overall position.

Insights

Equity compensation and insider trading analyst

CFO’s small Rule 10b5-1 tax sale is routine and low signal.

The filing shows SOPHiA GENETICS SA CFO George Cardoza sold 1,403 ordinary shares at a weighted average of $4.8472 on April 8, 2026. Footnotes state the sale was solely to satisfy tax withholding from restricted stock unit vesting.

The transactions occurred under a pre-established Rule 10b5-1 trading plan, meaning they were scheduled in advance and not timed at his discretion. Cardoza retains 291,458 shares afterward, so the sale is a small fraction of his holdings and appears to be routine compensation-related activity.

Insider Trade Summary 10b5-1

Net Seller: 1,403 shares ($6,801)

Net Sell 1 txn

Insider CARDOZA GEORGE

Role Chief Financial Officer

Sold 1,403 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,403	$4.8472	$7K

Holdings After Transaction: Ordinary Shares — 291,458 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.79 to $4.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,403 shares Weighted average sale price: $4.8472 per share Post-transaction holdings: 291,458 shares +1 more

4 metrics

Shares sold 1,403 shares Open-market sale on April 8, 2026

Weighted average sale price $4.8472 per share Ordinary Shares sold on April 8, 2026

Post-transaction holdings 291,458 shares Ordinary Shares held directly after the sale

Sale price range $4.79–$4.93 per share Multiple transactions within this range as disclosed in footnote

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARDOZA GEORGE

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/08/2026		S		1,403(1)	D	$4.8472(2)	291,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on April 2 and 3, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.79 to $4.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) CFO George Cardoza report in this Form 4?

He reported selling 1,403 ordinary shares of SOPHiA GENETICS SA. The sale occurred on 8 April 2026 at a weighted average price of about $4.85 per share, with the shares sold in open-market transactions as disclosed in the filing footnotes.

Why did SOPHiA GENETICS CFO George Cardoza sell 1,403 SOPH shares?

The filing states the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on 2 and 3 April 2026. This indicates a compensation-related, mechanistic sale rather than a discretionary decision to reduce his investment in the company.

Were George Cardoza’s SOPH share sales under a Rule 10b5-1 trading plan?

Yes. The footnotes explain that all reported sales were made under a pre-established Rule 10b5-1 trading plan. Such plans schedule trades in advance and are designed to reduce concerns that insiders are timing transactions based on nonpublic information or short-term market moves.

How many SOPHiA GENETICS (SOPH) shares does the CFO hold after this transaction?

After selling 1,403 shares, George Cardoza directly holds 291,458 ordinary shares. This indicates the sale covered only a small portion of his total position, consistent with a limited tax-withholding transaction tied to restricted stock unit vesting rather than a major reduction in holdings.

What price range did the SOPH shares sell for in the CFO’s Form 4 filing?

The reported weighted average sale price was $4.8472 per share. Footnotes note that multiple trades occurred between $4.79 and $4.93 inclusive. Cardoza has agreed to provide detailed price breakdowns for each individual transaction upon written request to investors or regulators.